Research programme: small molecule therapeutics - Inventiva Pharma

Drug Profile

Research programme: small molecule therapeutics - Inventiva Pharma

Alternative Names: EHMT2 inhibitors - Inventiva Pharma; Enhancer of zeste homolog 2 inhibitors - Inventiva Pharma; euchromatic histone-lysine N-methyltransferase 2 - Inventiva Pharma; EZH2 inhibitors - Inventiva Pharma; G9a inhibitors - Inventiva Pharma; histone-lysine N-methyltransferase inhibitors - Inventiva Pharma; NSD2 inhibitors - Inventiva Pharma; TEAD/YAP inhibitors - Inventiva Pharma; YAP/TEAD inhibitors - Inventiva Pharma

Latest Information Update: 11 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Inventiva Pharma
  • Developer Curie Institute; Inventiva Pharma
  • Class Antineoplastics; Small molecules
  • Mechanism of Action EZH2 enzyme inhibitors; Histone-lysine N-methyltransferase inhibitors; Immunomodulators; Protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Breast cancer; Lung cancer; Mesothelioma; Multiple myeloma; Non-Hodgkin's lymphoma; Ovarian cancer; Respiratory tract disorders; Skin cancer

Most Recent Events

  • 11 Sep 2017 Early research in Lung cancer in France before September 2017 (Inventiva Pharma pipeline, September 2017)
  • 11 Sep 2017 Early research in Mesothelioma in France before September 2017 (Inventiva Pharma pipeline, September 2017)
  • 20 Nov 2015 Early research in Breast cancer in France (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top